CEL-SCI (NYSE: CVM) is primarily focused on R&D to improve the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. Its lead investigational therapy, Multikine, is currently being studied in a pivotal global phase 3 clinical trial, and is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for rheumatoid arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. For more information, visit the company’s website at www.cel-sci.com